Reuters logo
BRIEF-Takeda and Seattle Genetics announce positive results from phase 3 ECHELON-1 clinical trial
June 26, 2017 / 10:50 AM / 3 months ago

BRIEF-Takeda and Seattle Genetics announce positive results from phase 3 ECHELON-1 clinical trial

June 26 (Reuters) - Seattle Genetics Inc

* Takeda and Seattle Genetics announce positive results from phase 3 ECHELON-1 clinical trial evaluating Adcetris in frontline advanced hodgkin lymphoma

* Says interim analysis of overall survival, key secondary endpoint, also trended in favor of Adcetris+AVD arm

* Says safety profile of Adcetris+AVD in trial was consistent with that known for single-agent components of regimen

* Says there was an increased incidence of febrile neutropenia and peripheral neuropathy in the Adcetris+AVD arm

* Takeda and Seattle Genetics plan to submit trial results to regulatory authorities for approval in respective territories

* phase 3 clinical trial met primary endpoint of statistically significant improvement in modified progression-free survival versus control arm Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below